What's the usual method for kadcyla delivery to patients?

How is Kadcyla (ado-trastuzumab emtansine) usually given to patients?

Kadcyla is delivered by intravenous (IV) infusion in a clinical setting, typically administered by healthcare professionals. Doses are given on a treatment schedule rather than as an at-home injection, because the medication is infused into a vein under medical supervision.

What does “delivery” look like in practice?

In practice, patients receive Kadcyla via an IV line during an infusion visit. The infusion is performed in an outpatient clinic or hospital infusion unit, where staff can monitor for infusion-related reactions and other side effects during and after dosing.

Are there circumstances that change how it’s delivered?

Yes. Administering teams may adjust infusion logistics based on factors such as patient tolerance and side effects. Clinicians can also hold or delay the next dose if adverse events occur, which affects when patients receive subsequent infusions.

How do patients commonly describe the experience?

Patients generally think of Kadcyla as an infusion appointment: they show up for dosing, receive the medication through the IV over the scheduled time, and then go home afterward if they remain stable.

Sources

No sources provided in the prompt.